Back

Natriuretic peptides reverse vascular insulin resistance and supress insulin-induced mechanisms of atherogenesis

30 August 2026 (17:15 - 17:45)
Organised by: Logo
Congress Presentation Part of: Innovative therapeutic strategies in coronary artery disease Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Daniel Foran

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Spinal Cord Stimulation in patients with Refractory Angina Pectoris (SCRAP); double-blind, placebo-controlled, cross-over randomized controlled trial
Miss F. Vervaat (Eindhoven, NL)
Abstract
Presentation thumbnail
The effects of STAtin-FENOfibrate combination therapy vs. statin monotherapy on necrotic core and plaque characteristics in non-diabetic patients with combined dyslipidemia and intermediate CAOD
Professor S. Han (Incheon, KR)
Abstract
Presentation thumbnail
Long-term adherence to secondary preventive medications after myocardial infarction: a post-hoc analysis of the BETAMI trial
Ms A. Bakken (Oslo, NO)
Abstract
Presentation thumbnail
Safety and efficacy of coronary sinus narrowing for treating refractory angina in real-world setting - single center experience
Ms J. Grygier (Poznan, PL)
Abstract

Access the full session

Session thumbnail
Innovative therapeutic strategies in coronary artery disease

The Event

Event poster

ESC Congress 2026

30 August 2026 17:15 CET
You may be interested in
thumbnail
Congress Presentation
B-type natriuretic peptide reverses vascular endothelial insulin resistance and ameliorates dysregulated redox signalling when administered alongside insulin in human atherosclerosis
31 August 2025
thumbnail
Congress Presentation
Low natriuretic peptide levels in heart failure with preserved ejection fraction
29 June 2021
thumbnail
Congress Presentation
Coronary microvascular dysfunction in INOCA: the potential role of endothelium-dependent hyperpolarisation assessed by subcutaneous fat tissue biopsy and wire myography
1 September 2025
thumbnail
Congress Presentation
Empagliflozin treatment does not affect the hypertensive response to Ang II administration to rats but decreases oxidative stress in the arterial wall, and endothelial and cardiac dysfunction
1 September 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources